{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:02:49Z","timestamp":1785355369991,"version":"3.55.0"},"reference-count":29,"publisher":"Begell House","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Eukaryot Gene Expr"],"published-print":{"date-parts":[[2026]]},"abstract":"<p>Synovial sarcoma (SS) is a malignant soft tissue sarcoma. Our previous study revealed that miR-9-5p aggravates SS development. The aim of current study is to explore the mechanism that regulating miR-9-5p expression in SS progression. RIP assay is performed to analyze the combination of DiGeorge syndrome critical region gene 8 (DGCR8) and nuclear factor &amp;kappa;B (NF-&amp;kappa;B) p65 with primary (pri)-miR-9-1, pri-miR-9-2 and pri-miR-9-3. Co-IP is used to detect the combination of DGCR8 and NF-&amp;kappa;B p65. Cell proliferation and apoptosis are analyzed using colony formation assay and flow cytometry, respectively. NF-&amp;kappa;B p65 and miR-9-5p are evaluated in SS tumors and they are positively correlation. In SS cells, NF-&amp;kappa;B p65 increasing promotes mature miR-9-5p expression, but inhibits pri-miR-9-1\/3 expression. NF-&amp;kappa;B p65 silencing results in opposite effects. Altering NF-&amp;kappa;B p65 level did not affect the expression of pri-miR-9-2. The binding of DGCR8 and pri-miR-9-1\/3 are attenuated by NF-&amp;kappa;B p65 silencing. The combination of NF-&amp;kappa;B p65 and DGCR8 is weakened by RNase treatment or NF-&amp;kappa;B p65 silencing. The inhibition of NF-&amp;kappa;B p65 to pri-miR-9-1\/3 expression and the promotion of NF-&amp;kappa;B p65 to miR-9-5p expression are rescued by DGCR8 silencing. Functional experiment results revealed that NF-&amp;kappa;B p65 overexpression promotes SS cell proliferation and suppresses cell apoptosis, but there are rescued by miR-9-5p silencing or DGCR8 silencing. Overall, NF-&amp;kappa;B p65 contributes the processing of pri-miR-9-1\/3 into mature miR-9-5p in a DGCR8-dependent manner. Meantime, NF-&amp;kappa;B p65 promotes SS cell proliferation and inhibits SS cell apoptosis by promoting miR-9-5p expression. Our data provided a novel evidence for miR-9-5p serving as a promising target for SS therapy, and proposed a novel regulatory mechanism for SS development.<\/p>","DOI":"10.1615\/critreveukaryotgeneexpr.2026063403","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:57:15Z","timestamp":1778774235000},"page":"15-28","source":"Crossref","is-referenced-by-count":0,"title":["Nuclear Factor &amp;kappa;B p65 Regulates Synovial Sarcoma Development through a DGCR8-Dependent Signaling Pathway"],"prefix":"10.1615","volume":"36","author":[{"given":"Xuezheng","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"613","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Nielsen TO, Poulin NM, Ladanyi M. Synovial sarcoma: Recent discoveries as a roadmap to new avenues for therapy. Cancer Discov. 2015;5:124-\u0080\u009334.","DOI":"10.1158\/2159-8290.CD-14-1246"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Fiore M, Sambri A. The biology of synovial sarcoma: State-of-the-art and future perspectives. Curr Treat Options Oncol. 2021;22:109.","DOI":"10.1007\/s11864-021-00914-4"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Wang AX, Jones KB. Molecular and epigenetic oncogenesis in synovial sarcoma: Implications for cancer biology, diagnosis and treatment. Oncogene. 2025;44:3527-\u0080\u009336.","DOI":"10.1038\/s41388-025-03547-1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Tazzari M, Bergamaschi L, De Vita A. Molecular determinants of soft tissue sarcoma immunity: Targets for immune intervention. Int J Mol Sci. 2021;22:7518.","DOI":"10.3390\/ijms22147518"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Blay JY, von Mehren M, Jones RL, Martin-Broto J, Stacchiotti S, Bauer S, Gelderblom H, Orbach D, Hindi N, Dei Tos A, Nathenson M. Synovial sarcoma: Characteristics, challenges, and evolving therapeutic strategies. ESMO Open. 2023;8:101618.","DOI":"10.1016\/j.esmoop.2023.101618"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Recine F, Vanni S, Bongiovanni A, Fausti V, Mercatali L, Miserocchi G, Liverani C, Pieri F, Casadei R, Cavaliere D, Falbo PT, Diano D, Ibrahim T, De Vita A. Clinical and translational implications of immunotherapy in sarcomas. Front Immunol. 2024;15:1378398.","DOI":"10.3389\/fimmu.2024.1378398"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Landuzzi L, Manara MC. Innovative breakthroughs for the treatment of advanced and metastatic synovial sarcoma. Cancers. 2023;15:3887.","DOI":"10.3390\/cancers15153887"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Desar IME, Fleuren EDG, van der Graaf WTA. Systemic treatment for adults with synovial sarcoma. Curr Treat Options Oncol. 2018;19:13.","DOI":"10.1007\/s11864-018-0525-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"La Ferlita A, Sp N. Small non-coding RNAs in soft-tissue sarcomas: State of the art and future directions. Mol Cancer Res. 2023;21:511-\u0080\u009324.","DOI":"10.1158\/1541-7786.MCR-22-1008"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Zhang L, Zhang W, Peng H, Shen T, Wang M, Luo M, Qu X, Qu F, Liu W, Lei B, Yang S. Bioactive cytomembrane@ poly(citrate-peptide)-miRNA365 nanoplatform with immune escape and homologous targeting for colon cancer therapy. Mater Today Bio. 2022;15:100294.","DOI":"10.1016\/j.mtbio.2022.100294"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Xu XZ, Li XA, Luo Y, Liu JF, Wu HW, Huang G. miR-9 promotes synovial sarcoma cell migration and invasion by directly targeting CDH1. Int J Biochem Cell Biol. 2019;112:61-\u0080\u009371.","DOI":"10.1016\/j.biocel.2019.04.001"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Correia de Sousa M, Gjorgjieva M, Dolicka D, Sobolewski C, Foti M. Deciphering miRNAs' action through miRNA editing. Int J Mol Sci. 2019;20(24):6249.","DOI":"10.3390\/ijms20246249"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Kakumani PK, Ko Y, Ramakrishna S, Christopher G, Dodgson M, Shrinet J, Harvey LM, Shin C, Simard MJ. CSDE1 promotes miR-451 biogenesis. Nucleic Acids Res. 2023;51:9385-\u0080\u009396.","DOI":"10.1093\/nar\/gkad619"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Bofill-De Ros X, Kasprzak WK, Bhandari Y, Fan L, Cavanaugh Q, Jiang M, Dai L, Yang A, Shao TJ, Shapiro BA, Wang YX, Gu S. Structural differences between PrimiRNA paralogs promote alternative drosha cleavage and expand target repertoires. Cell Rep. 2019;26:447-\u0080\u009359. e444.","DOI":"10.1016\/j.celrep.2018.12.054"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Wang J, Gu Z, Ni P, Qiao Y, Chen C, Liu X, Lin J, Chen N, Fan Q. NF-kappaB P50\/P65 hetero-dimer mediates differential regulation of CD166\/ALCAM expression via interaction with micoRNA-9 after serum deprivation, providing evidence for a novel negative auto-regulatory loop. Nucleic Acids Res. 2011;39:6440-\u0080\u009355.","DOI":"10.1093\/nar\/gkr302"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Mirzaei S, Saghari S, Bassiri F, Raesi R, Zarrabi A. NF-\u03baB as a regulator of cancer metastasis and therapy response: A focus on epithelial-mesenchymal transition. J Cell Physiol. 2022;237:2770-\u0080\u009395.","DOI":"10.1002\/jcp.30759"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431-\u0080\u00936.","DOI":"10.1038\/nature04870"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Park HH, Kim HR, Park SY, Hwang SM, Hong SM, Park S, Kang HC, Morgan MJ, Cha JH, Lee D, Roe JS, Kim YS. RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment. Mol Cancer. 2021;20:107.","DOI":"10.1186\/s12943-021-01399-3"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Horiuchi K, Morioka H, Nishimoto K, Suzuki Y, Susa M, Nakayama R, Kawai A, Sonobe H, Takaishi H, Ozaki T, Yabe H, Umezawa K, Toyama Y. Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ). Cancer Lett. 2008;272: 336-\u0080\u009344.","DOI":"10.1016\/j.canlet.2008.07.021"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Thomas-Jardin SE, Dahl H, Nawas AF, Bautista M, Delk NA. NF-\u03baB signaling promotes castration-resistant prostate cancer initiation and progression. Pharmacol Ther. 2020;211:107538.","DOI":"10.1016\/j.pharmthera.2020.107538"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Kaur P, Verma S, Kushwaha PP, Gupta S. EZH2 and NF-\u03baB: A context-dependent crosstalk and transcriptional regulation in cancer. Cancer Lett. 2023;560:216143.","DOI":"10.1016\/j.canlet.2023.216143"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Pelletier D, Rivera B, Fabian MR, Foulkes WD. miRNA biogenesis and inherited disorders: Clinico-molecular insights. Trends Genet. 2023;39:401-\u0080\u009314.","DOI":"10.1016\/j.tig.2023.01.009"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Wang L, Cui M, Cheng D, Qu F, Yu J, Wei Y, Cheng L, Wu X, Liu X. miR-9-5p facilitates hepatocellular carcinoma cell proliferation, migration and invasion by targeting ESR1. Mol Cell Biochem. 2021;476:575-\u0080\u009383.","DOI":"10.1007\/s11010-020-03927-z"},{"key":"24","unstructured":"Wei YQ, Jiao XL, Zhang SY, Xu Y, Li S, Kong BH. miR-9-5p could promote angiogenesis and radiosensitivity in cervical cancer by targeting SOCS5. Eur Rev Med Pharmacol Sci. 2019;23:7314-\u0080\u009326."},{"key":"25","doi-asserted-by":"crossref","unstructured":"Yamazaki T, Tukiyama T, Tokiwa T. Effect of dexamethasone on binding activity of transcription factors nuclear factor-kappaB and activator protein-1 in SW982 human synovial sarcoma cells. In Vitro Cell Dev Biol Anim. 2005;41:80-\u0080\u00932.","DOI":"10.1290\/0502011.1"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Tamiya H, Urushihara N, Shizuma K, Ogawa H, Nakai S, Wakamatsu T. SHARPIN enhances ferroptosis in synovial sarcoma cells via NF-\u00ce\u00baB- and PRMT5-mediated PGC1\u00ce\u00b1 reduction. Cancers. 2023;15:3484.","DOI":"10.3390\/cancers15133484"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Macias S, Cordiner RA, Gautier P, Plass M, C\u00e1ceres JF. DGCR8 acts as an adaptor for the exosome complex to degrade double-stranded structured RNAs. Mol Cell. 2015;60:873-\u0080\u009385.","DOI":"10.1016\/j.molcel.2015.11.011"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Michlewski G, C\u00e1ceres JF. Post-transcriptional control of miRNA biogenesis. RNA. 2019;25:1-\u0080\u009316.","DOI":"10.1261\/rna.068692.118"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Nogami M, Miyamoto K, Hayakawa-Yano Y, Nakanishi A, Yano M, Okano H. DGCR8-dependent efficient pri-miRNA processing of human pri-miR-9-2. J Biol Chem. 2021;296:100409.","DOI":"10.1016\/j.jbc.2021.100409"}],"container-title":["Critical Reviews in Eukaryotic Gene Expression"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/5c7af3f26fe4a7b1\/CRE-63403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:16:39Z","timestamp":1785352599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/6dbf508d3b17c437,320bc5320bccf579,5c7af3f26fe4a7b1.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1615\/critreveukaryotgeneexpr.2026063403","relation":{},"ISSN":["1045-4403"],"issn-type":[{"value":"1045-4403","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}